Health Law Alliance is publishing this alert to inform pharmacies and providers of a significant enforcement trend that could have serious implications for your business operations. ESI has drastically increased the number of audits it conducts of telehealth relationships, including providers that have contractual relationships with a provider named EZScripts. If you are doing business with EZScripts or other telehealth platforms, you will be subject to increased scrutiny from ESI and other PBMs.
Claim Phishing Audits on the Rise
Telehealth platforms often use pharmacies' National Provider Identifier (NPI) number to run "test" claims, often referred to as benefits eligibility checks.
PBMs and other entities involved in the claims adjudication process, such as McKesson's RelayHealth "switch," typically use "terms and conditions" and other contractual provisions to prohibit these transmissions.
ESI is now attempting to recoup on claims that are associated with these eligibility checks, irrespective that the claims are reversed and not paid. Specifically, ESI is demanding that pharmacies repay the entire amount at issue, meaning the entire dollar value arising from both paid and test claims.
This situation is deeply concerning. ESI is not only reclaiming all reimbursements made to these pharmacies, but also seeking to recover the monetary value of test claims for which pharmacies were never reimbursed, placing the financial stability of numerous pharmacies in jeopardy.
We Defend You Against ESI
If your pharmacy has done business with telehealth platforms such as Noble or EZScripts, and you have received an audit notice from ESI, we strongly urge you to contact us immediately. Our experienced PBM audit attorneys will provide you with a free consultation to discuss your options and provide the legal guidance necessary to protect your pharmacy from potentially devastating financial repercussions. Schedule a free consultation now.
MORE ARTICLES BY CATEGORY
HLA's Diana Yastrovskaya Featured on Live TV for PBM Expertise
The feature underscores HLA’s mission to elevate thought leadership within the healthcare space and provide trusted expertise on issues that directly impact patients, providers, and policymakers.
Read More >>By Appointment Only: How DME Suppliers Can Prevent Unexpected DME License Revocations
DME suppliers can prevent unexpected and costly license revocations by strategically applying with a "By Appointment Only" designation. This article explores the common compliance trap of failing unannounced site visits due to conflicts between standard pharmacy operating hours and Medicare's "posted hours" requirement for DME suppliers. "By Appointment Only" status is a crucial safeguard, which suppliers can take to implement to protect their DME billing privileges.
Read More >>Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing
Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.
Read More >>9th Circuit’s Landmark EKRA Ruling—What Providers Should Know
On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.
Read More >>
